Evidence map›Paper›PMID 27168718›Full record

ArticleMolecular vision2016

Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy.

Ahmed M Abu El-Asrar, Mohammad Mairaj Siddiquei, Mohd Imtiaz Nawaz, Gert De Hertogh, Ghulam Mohammad, Kaiser Alam, Ahmed Mousa, Ghislain Opdenakker

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Molecular vision, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Protective Effect of Tang Wang One Decoction on the Retinal Vessels of Diabetic Rats.Evidence-based complementary and alternative medicine : eCAM · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Ahmed M Abu El-AsrarDepartment of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Dr. Nasser Al-Rashid Research Chair in Ophthalmology.
Mohammad Mairaj SiddiqueiDepartment of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Mohd Imtiaz NawazDepartment of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Gert De HertoghLaboratory of Histochemistry and Cytochemistry, University of Leuven, KU Leuven, Leuven, Belgium.
Ghulam MohammadDepartment of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Kaiser AlamDepartment of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Ahmed MousaDepartment of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Ghislain OpdenakkerRega Institute for Medical Research, Department of Microbiology and Immunology, University of Leuven, KU Leuven, Leuven, Belgium.
King Saud University · SAKU Leuven · BERega Institute for Medical Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHeparanase cleaves heparan sulfate side chains of heparan sulfate proteoglycans, activity that is implicated in angiogenesis. Proteolytic cleavage of proheparanase by cathepsin L leads to the formation of catalytically active heparanase. We investigated the expression levels of heparanase enzymatic activity and correlated these with the levels of cathepsin L, the angiogenic factors tissue factor (TF) and matrix metalloproteinase-9 (MMP-9), and the angiostatic factor tissue factor pathway inhibitor (TFPI) in proliferative diabetic retinopathy (PDR).

methodsVitreous samples from 25 patients with PDR and 20 nondiabetic patients and epiretinal membranes from 12 patients with PDR were studied with enzyme-linked immunosorbent assay, western blot analysis, and immunohistochemistry.

resultsWe observed a significant increase in the expression of heparanase activity in vitreous samples from patients with PDR compared to the nondiabetic controls (p=0.027). Significant positive correlations were found between the levels of heparanase activity and the levels of cathepsin L (r=0.51; p=0.001), TF (r=0.6; p<0.0001), and TFPI (r=0.49; p=0.001). The expression levels of cathepsin L (p=0.019), TF (p<0.0001), TFPI (p<0.0001), and MMP-9 (p=0.029) were significantly higher in the vitreous samples with detected heparanase activity compared to the vitreous samples with undetected heparanase activity. Western blot analysis demonstrated proteolytic cleavage of TFPI in the vitreous samples from patients with PDR. In the epiretinal membranes, cathepsin L, TF, and TFPI were expressed in vascular endothelial cells and CD45-expressing leukocytes. Significant positive correlations were detected between the number of blood vessels that expressed CD31 and the number of blood vessels that expressed TF (r=0.9; p<0.0001) and TFPI (r=0.81; p=0.001).

conclusionsThe coexpression of these angiogenesis regulatory factors suggests cross-talk between these factors and pathogenesis of PDR angiogenesis.

Indexed as

AdultAgedBlotting, WesternCathepsin LDiabetic RetinopathyEnzyme-Linked Immunosorbent AssayEpiretinal MembraneFemaleGlucuronidaseHeparanaseHumansImmunohistochemistryLipoproteinsMaleMatrix Metalloproteinase 9Middle AgedCathepsin LGlucuronidaseHeparanaselipoprotein-associated coagulation inhibitorLipoproteinsMatrix Metalloproteinase 9MMP9 protein, human

Identifiers

PMID27168718
PMCPMC4851855
OpenAlexW2347003793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.